protocolSection identificationModule nctId: NCT06283641, orgStudyIdInfo id: NN8022-7780, secondaryIdInfos id: U1111-1289-9747, type: OTHER, domain: World Health Organization (WHO), briefTitle: Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan., statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-02-23, primaryCompletionDateStruct date: 2025-02-28, completionDateStruct date: 2025-02-28, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Novo Nordisk A/S, class: INDUSTRY, descriptionModule briefSummary: This is a non-interventional study to evaluate the safety and effectiveness of Saxenda® in obese adults and adolescents in Taiwan. The participants will recieve Saxenda® treatment which is a medicine that doctors can already prescribe.The study will last for about 26 weeks., conditionsModule conditions: Obesity, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 288, type: ESTIMATED, armsInterventionsModule interventions name: Liraglutide, outcomesModule primaryOutcomes measure: Incidence of adverse events (AEs) by preferred term (PT), secondaryOutcomes measure: Number of adverse drug reaction (ADRs), secondaryOutcomes measure: Number of serious adverse events (SAEs) and serious adverse drug reactions (SADRs), secondaryOutcomes measure: Number of unexpected AEs and unexpected ADRs, secondaryOutcomes measure: Number of unexpected SAEs and unexpected SADRs, secondaryOutcomes measure: Dose and exposure of liraglutide after initiation and reasons if not escalate to liraglutide 3.0 miligram (mg) for maintenance as specified in the product label, secondaryOutcomes measure: Body weight loss Percent (%) (Adult), secondaryOutcomes measure: Body weight loss (%) (Adult), secondaryOutcomes measure: Body weight loss Kilogram(Kg) (Adult), secondaryOutcomes measure: Body weight loss (kg) (Adult), secondaryOutcomes measure: The proportion of adult subjects losing at least 5% of baseline body weight, secondaryOutcomes measure: The proportion of adult subjects losing at least 5% of baseline body weight, secondaryOutcomes measure: The proportion of adult subjects losing more than 10% of baseline body weight, secondaryOutcomes measure: The proportion of adult subjects losing more than 10% of baseline body weight, secondaryOutcomes measure: The proportion of losing at least 5% of baseline body weight from adult subjects whose maintenance dose of 3 mg, 12- week Saxenda®, secondaryOutcomes measure: Change in body mass index (BMI) (kg/m^2) (Adolescent), secondaryOutcomes measure: Change in body mass index (BMI) (kg/m^2) (Adolescent), secondaryOutcomes measure: Change in body mass index (BMI) (%) (Adolescent), secondaryOutcomes measure: Change in body mass index (BMI) (%) (Adolescent), secondaryOutcomes measure: Change in body mass index standard deviation score (BMI SDS) (Adolescent), secondaryOutcomes measure: Change in body mass index standard deviation score (BMI SDS) (Adolescent), secondaryOutcomes measure: Body weight loss (%) (Adolescent), secondaryOutcomes measure: Body weight loss (%) (Adolescent), secondaryOutcomes measure: Body weight loss (kg) (Adolescent), secondaryOutcomes measure: Body weight loss (kg) (Adolescent), secondaryOutcomes measure: The proportion of adolescent subjects losing at least 4% of baseline BMI, secondaryOutcomes measure: The proportion of adolescent subjects losing at least 4% of baseline BMI, secondaryOutcomes measure: The proportion of adolescent subjects losing at least 10% of baseline BMI, secondaryOutcomes measure: The proportion of adolescent subjects losing at least 10% of baseline BMI, secondaryOutcomes measure: The proportion of losing at least 4% of baseline BMI from adolescent subjects whose maintenance dose of 3 mg or maximum tolerated dose, 12- week Saxenda®, eligibilityModule sex: ALL, minimumAge: 12 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Taiwan University Hospital, city: Taipei City, zip: 100229, country: Taiwan, geoPoint lat: 25.04776, lon: 121.53185, locations facility: National Taiwan University Hospital, city: Taipei City, zip: 100, country: Taiwan, geoPoint lat: 25.04776, lon: 121.53185, hasResults: False